.Attributes Medication, Posted online: 16 Oct 2024 doi:10.1038/ s41591-024-03348-1Publisher Adjustment: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a period 1 trial.
Universal Insights Knowledge Hub
Hub for knowledge on universal insights covering news, finance, technology, health, and lifestyle.
.Attributes Medication, Posted online: 16 Oct 2024 doi:10.1038/ s41591-024-03348-1Publisher Adjustment: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a period 1 trial.